Tvardi Therapeutics, Inc. (TVRD): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 07:05 ET
- Event date
- 2026-11-13
- Accession no.
- 0001104659-26-126507
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Tvardi reports third quarter results and updates clinical trial plans
Tvardi reported a $6.1 million net loss for the quarter ended September 30, 2026, versus $5.5 million in the comparable period in 2025. It expects existing cash to fund planned operations into the third quarter of 2027. The company expects TTI-101 liver cancer topline data early in the first quarter of 2027 and plans a TTI-109 ulcerative colitis trial in 2027, subject to IND clearance and additional funding.
- Net loss was $6.1 million for the three months ended September 30, 2026, compared to $5.5 million for the comparable period in 2025.
- Cash and cash equivalents were $22.3 million as of September 30, 2026; planned operations are funded into the third quarter of 2027.
- Tvardi expects TTI-101 Phase 1b/2 HCC topline data early in the first quarter of 2027.
- A TTI-109 ulcerative colitis clinical trial is planned for 2027, subject to IND clearance and additional funding.
earningsguidanceproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | tvrd-20261113x8k.htm |
| EX-99.1 | EX-99.1 | tvrd-ex99d1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.